Cell>Point

Cell>Point is a biotechnology company developing universal molecular imaging agents and intra-nuclear metallic therapeutics.

The cornerstone of Cell>Point is metabolic imaging and therapeutic targeting through intra-nuclear chelation technology. The company is developing universal oncology, cardiology, stroke and diabetes molecular imaging agents, and intra-nuclear metallic therapeutics. Cell>Point is a privately held biotechnology company with offices in Centennial, Colorado, Houston and Saratoga, California. The company’s five technology platforms, ethylenedicysteine drug conjugate technology (“EC Technology”), In-Situ Hydrogel (“In Situ Hydrogel Technology”), tetraazacyclopentadecane technology (“N4 Technology”), oligosaccharide conjugate technology (“Dual Agent Technology”) and mechanism-based targeted pancreatic beta cell technology (“Beta Cell Technology”) are being developed to create new radiodiagnostic imaging agents, new intra-nuclear therapeutic agents, and high yield delivery systems for the administration of local regional radio/chemotherapy.